Adamis Pharmaceuticals (NASDAQ:ADMP) Coverage Initiated by Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) in a note issued to investors on Sunday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Adamis Pharmaceuticals Stock Performance

NASDAQ:ADMP opened at $0.05 on Friday. The stock’s 50 day moving average price is $0.10 and its 200 day moving average price is $0.16. Adamis Pharmaceuticals has a 52 week low of $0.05 and a 52 week high of $0.55.

Hedge Funds Weigh In On Adamis Pharmaceuticals

A hedge fund recently raised its stake in Adamis Pharmaceuticals stock. State Street Corp raised its stake in shares of Adamis Pharmaceuticals Co. (NASDAQ:ADMP – Get Rating) by 13.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 475,373 shares of the specialty pharmaceutical company’s stock after purchasing an additional 55,168 shares during the period. State Street Corp owned 0.32% of Adamis Pharmaceuticals worth $271,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.57% of the company’s stock.

About Adamis Pharmaceuticals

(Get Rating)

Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company provides products in various therapeutic areas, including allergy, respiratory, opioid overdose, and erectile dysfunction markets.